Improving Graft Outcomes for the Long Term

This activity has expired. The accredited provider can no longer issue certificates for this activity. Strategically Speaking cannot attest to the timeliness of expired CME activities.

EDUCATIONAL OBJECTIVES

• Review registry data and long-term graft survival data
• Discuss practical strategies to optimize the use of immunosuppressants while minimizing toxicity
• Discuss patient health outcome measures as a key metric in improving long-term outcomes
• Discuss the impact of metabolic abnormalities on outcomes
• Provide expert recommendations to optimize the long-term management of posttransplant patients
• Identify “risk factors” to tailor long-term immunosuppressive therapy to optimize patient outcomes
  • Review of select patient populations and expert recommendations based on clinical evidence to optimize patient outcomes
  • Provide strategies to maintain therapeutic doses of MPA therapy in response to adverse drug reactions
  • Review evidence-based literature pertaining

Disclosure Policy
The University of Massachusetts Medical School requires that CME faculty disclose, during the planning of an activity, the existence of any personal financial or other relationships they or their spouses/partners have with the commercial supporter of the activity or with the manufacturer of any commercial product or service discussed in the activity.

The faculty represents the following relationships:

Paul Bolin, Jr., MD
Grant/Research Support: Astellas Pharma US, Inc; Novartis Pharmaceuticals Corporation
Consultant: Novartis Pharmaceuticals Corporation
Speaker’s Bureau: Novartis Pharmaceuticals Corporation


Ronald Ferguson, Jr., MD
Grant/Research Support: Astellas Pharma US, Inc; Novartis Pharmaceuticals Corporation; Roche Pharmaceuticals; Wyeth Pharmaceuticals
Consultant: Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals, Wyeth Pharmaceuticals
Speaker’s Bureau: Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals, Wyeth Pharmaceuticals


John Gill, MD
I have no actual or potential conflict of interest in relation to this program/presentation.


Shamkant Mulgaonkar, MD
Grant/Research Support: Astellas Pharma US, Inc; Genzyme Corporation; Lifecycle Biopharma Limited; Novartis Pharmaceuticals Corporation; Pfizer Inc; Roche Pharmaceuticals; Wyeth Pharmaceuticals
Consultant: Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals
Speaker’s Bureau: Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals


Hans Sollinger, MD
Grant/Research Support: Astellas Pharma US, Inc; Novartis Pharmaceuticals Corporation


Gregory A. Volturo, MD
I have no actual or potential conflict of interest in relation to this program/presentation.

AGENDA

12:45 PM – 12:50 PM	Introduction and Program Overview
	Hans Sollinger, MD, PhD
	Folkert O. Belzer Professor of Surgery
	Chairman, Division of Transplantation
	University of Wisconsin – Madison
	Madison, Wisconsin
12:50 PM – 1:10 PM	Patient-centric Health Outcomes
	Shamkant Mulgaonkar, MD
	Chief, Renal and Pancreas Transplant Division
	St. Barnabas Health Care System
	Livingston, New Jersey
1:10 PM – 1:30 PM	Why have long-term graft rejection rates not improved significantly?
	Paul Bolin, Jr., MD
	Professor and Interim Chair
	Department of Internal Medicine
	Chief, Division of Nephrology and Hypertension
	The Brody School of Medicine at East Carolina University
	Greenville, North Carolina
1:30 PM – 1:45 PM	History of IMPDH Inhibitors
	Hans Sollinger, MD, PhD
1:45 PM – 2:00 PM	Panel Discussion
	Ronald Ferguson, MD, PhD
	Director, Comprehensive Transplant Center
	Professor of Surgery
	The Ohio State University Medical Center
	Columbus, Ohio
	John Gill, MD
	Associate Professor of Medicine
	University of British Columbia
	St. Paul’s Hospital
	Vancouver, Canada